Article
Indianapolis-Intermittent diplopia is particularly problematic for physicians.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia
3 Things You Should Know About Interventional Glaucoma Comanagement
Q&A: A VERONA trial update with Yasha S. Modi, MD
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Opus Genetics partners with Global RDH12 Alliance
Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer